Bailly Creat

Bailly Creat, also known as Bailly-Creat or French pharmaceutical laboratory Bailly-Creat, is a French-based pharmaceutical company specializing in the production of dry-form drugs. This specialization indicates a focus on solid dosage formulations such as tablets or capsules, a common but critical segment of the pharmaceutical manufacturing supply chain. The company operates within the highly regulated European pharmaceutical sector, serving markets that require strict adherence to production standards for patient safety. While its exact scale, client base, and geographic reach are not detailed in available information, its identification as a laboratory confirms its role in the development and manufacturing phase of the drug lifecycle. The firm's operational profile places it among entities that manage sensitive intellectual property, clinical data, and proprietary formulation processes, making it a potential target for cyber espionage or extortion. Its status as an independent French entity, without any mentioned parent company or subsidiary relationships, suggests it may be a domestic operator within the broader European pharmaceutical landscape.

The company's recent history is notably defined by two significant cybersecurity incidents in late 2020, both attributed to the Doppel ransomware group. In early November 2020, Bailly Creat suffered a compromise where attackers infiltrated its IT systems and exfiltrated hundreds of internal documents. This breach was unusual for a ransomware attack, as the threat actors did not issue a ransom demand or deadline. Instead, months after the initial intrusion, Doppel publicly released a portion of the stolen data, an action indicating the attackers had determined a ransom payment would not be forthcoming. The remaining exfiltrated data may have been sold to other malicious actors, prolonging the potential for sensitive corporate information to be misused. A subsequent, related incident was reported in mid-November 2020, describing unauthorized access to the company's systems, though specific impacts from that event were not elaborated. These events position Bailly Creat as a case study in the pharmaceutical sector's vulnerability to data-centric extortion plots that extend beyond traditional encryption-based ransomware, highlighting the persistent risk of long-term data exposure following a security failure.